Key clinical point: A systematic proteogenomic analysis has revealed novel insights into the underlying molecular and immune mechanisms of endometrial carcinoma.
Major finding: The measurement of tumor antigen presentation defects could be more effective than measuring tumor mutation burden in the selection of immunotherapy for patients with endometrial carcinoma.
Study details: A multiomic analysis of 95 endometrial carcinoma tumor samples.
Disclosures: The study was funded by the National Cancer Institute, the Cancer Prevention & Research Institutes of Texas, and the Robert and Janice McNair Foundation. The authors reported having no conflicts of interest.
Dou Y et al. Cell. 2020 Feb 13. doi: 10.1016/j.cell.2020.01.026.